Quantitative and dynamic ctDNA as a biomarker of response and survival in patients with advanced lung squamous cell carcinoma receiving immunochemotherapy or chemotherapy alone
Introduction: Although circulating tumor DNA (ctDNA) dynamics have been widely explored for therapeutic response assessment, standardized methodologies remain elusive. Here, we developed MinerVa-Delta, a novel approach to quantify ctDNA dynamics by calculating weighted mutation changes in samples with multiple tracked variants. Methods: MinerVa-Delta was developed and analytically validated using serially diluted reference samples. The optimal cutoff was determined in a discovery cohort of 227 patients with advanced lung squamous cell carcinoma (LUSC) receiving programmed cell death protein 1 blockade plus chemotherapy or chemotherapy alone and further validated in an independent cohort of 97 patients with LUSC treated with chemotherapy alone. Variants were de novo called in pretreatment samples using a 769-gene next-generation sequencing panel, serving as a basis for personalized variant tracking in posttreatment plasma after two cycles of treatment. We applied MinerVa-Delta to evaluate prognosis and therapeutic response in advanced LUSC.
Results: Patients classified as molecular responders (MinerVa-Delta <30%) exhibited significantly improved outcomes compared with nonresponders (MinerVa-Delta ≥30%), with superior progression-free survival (hazard ratio = 0.19, p < 0.001) and overall survival (hazard ratio = 0.24, p < 0.001). MinerVa-Delta displayed consistent prediction performance in the validation cohort. Furthermore, MinerVa-Delta accurately identified radiologic stable disease patients, a clinically heterogeneous population, who could benefit from initial treatment.
Conclusions: Our findings suggest MinerVa-Delta is feasible for evaluating treatment response in patients with advanced LUSC. Integrating ctDNA profiling with conventional imaging could enhance response assessment, particularly in radiologic stable disease patients, enabling more precise therapeutic decision-making.
@article{Zhou2025MinervaDelta,title={Quantitative and dynamic ctDNA as a biomarker of response and survival in patients with advanced lung squamous cell carcinoma receiving immunochemotherapy or chemotherapy alone},author={Zhou, F and Zhang, J and Ren, S and Chen, J and Li, F and Ma, T and Fang, Y and Wang, Q and Yao, W and Guo, R and Lv, D and Cang, S and Dong, X and Wang, H and Yang, N and Fan, Y and Cui, J and Wang, Z and He, J and Huang, YS and Chen, W and Xu, LD and Zhou, C},journal={Journal of Thoracic Oncology},year={2025},doi={10.1016/j.jtho.2025.05.021},url={https://doi.org/10.1016/j.jtho.2025.05.021},dimensions={true},}
plasmaMSI
A Systematic Method to Detect Next-Generation Sequencing–Based Microsatellite Instability in Plasma Cell-Free DNA: plasmaMSI
Microsatellite instability (MSI) detection using tumor tissue is a well-established prognostic and predictive biomarker for certain types of cancers. However, tumor tissue samples are less convenient to obtain than blood plasma samples. The main challenge facing next-generation sequencing–based MSI detection in blood plasma samples is the ultralow signal/noise ratio in plasma cell-free DNA (cfDNA). To address the challenge, plasmaMSI, a highly accurate cfDNA MSI detection method, is introduced with three novel performance-improving features: i) a set of stringent locus selection criteria to select loci with high robustness and compatibility across sequencing platforms; ii) a new deduplication strategy that greatly improves the signal/noise ratio for MSI detection; and iii) an MSI calling algorithm that customizes the baseline for each test sample based on its duplication rate. Through analytical validation in diluted cell line samples, the limit of detection of plasmaMSI was determined to be 0.15%. Furthermore, in analyzing 95 evaluable cfDNA samples from patients with gastrointestinal cancers, plasmaMSI exhibited a positive percentage agreement of 92.9% (39/42) and a negative percentage agreement of 100% (53/53) with tissue MSI-PCR. plasmaMSI provides novel solutions to key challenges in cfDNA MSI detection that have not been addressed by existing methods. It has also been systematically validated and is already used in clinical testing for patients with cancer.
@article{Huang2025plasmaMSI,title={A Systematic Method to Detect Next-Generation Sequencing–Based Microsatellite Instability in Plasma Cell-Free DNA: plasmaMSI},author={Huang, F and Zhao, L and Xie, H and Han, T and Huang, J and Wang, X and Yang, J and Hong, Y and Shu, J and Yu, J and Li, Q and He, J and Chen, W and Huang, YS and Li, W},journal={Journal of Molecular Diagnostics},year={2025},doi={10.1016/j.jmoldx.2024.10.002},url={https://doi.org/10.1016/j.jmoldx.2024.10.002},dimensions={true},}
2024
TOTEM
TOTEM: a multi-cancer detection and localization approach using circulating tumor DNA methylation markers
Background: Detection of cancer and identification of tumor origin at an early stage improve the survival and prognosis of patients. Herein, we proposed a plasma cfDNA-based approach called TOTEM to detect and trace the cancer signal origin (CSO) through methylation markers.
Methods: We performed enzymatic conversion-based targeted methylation sequencing on plasma cfDNA samples collected from a clinical cohort of 500 healthy controls and 733 cancer patients with seven types of cancer (breast, colorectum, esophagus, stomach, liver, lung, and pancreas) and randomly divided these samples into a training cohort and a testing cohort. An independent validation cohort of 143 healthy controls, 79 liver cancer patients and 100 stomach cancer patients were recruited to validate the generalizability of our approach.
Results: A total of 57 multi-cancer diagnostic markers and 873 CSO markers were selected for model development. The binary diagnostic model achieved an area under the curve (AUC) of 0.907, 0.908 and 0.868 in the training, testing and independent validation cohorts, respectively. With a training specificity of 98%, the specificities in the testing and independent validation cohorts were 100% and 98.6%, respectively. Overall sensitivity across all cancer stages was 65.5%, 67.3% and 55.9% in the training, testing and independent validation cohorts, respectively. Early-stage (I and II) sensitivity was 50.3% and 45.7% in the training and testing cohorts, respectively. For cancer patients correctly identified by the binary classifier, the top 1 and top 2 CSO accuracies were 77.7% and 86.5% in the testing cohort (n=148) and 76.0% and 84.0% in the independent validation cohort (n=100). Notably, performance was maintained with only 21 diagnostic and 214 CSO markers, achieving a training AUC of 0.865, a testing AUC of 0.866, and an integrated top 2 accuracy of 83.1% in the testing cohort.
Conclusions: TOTEM demonstrates promising potential for accurate multi-cancer detection and localization by profiling plasma methylation markers. The real-world clinical performance of our approach needs to be investigated in a much larger prospective cohort.
@article{XiongHan2024TOTEM,title={TOTEM: a multi-cancer detection and localization approach using circulating tumor DNA methylation markers},author={Xiong, D and Han, T and Li, Y and Hong, Y and Li, S and Li, X and Tao, W and Huang, YS and Chen, W and Li, C},journal={BMC cancer},year={2024},doi={10.1186/s12885-024-12626-7},url={https://doi.org/10.1186/s12885-024-12626-7},dimensions={true},}
2023
Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization
Multimodal epigenetic characterization of cell-free DNA (cfDNA) could improve the performance of blood-based early cancer detection. However, integrative profiling of cfDNA methylome and fragmentome has been technologically challenging. Here, we adapt an enzyme-mediated methylation sequencing method for comprehensive analysis of genome-wide cfDNA methylation, fragmentation, and copy number alteration (CNA) characteristics for enhanced cancer detection. We apply this method to plasma samples of 497 healthy controls and 780 patients of seven cancer types and develop an ensemble classifier by incorporating methylation, fragmentation, and CNA features. In the test cohort, our approach achieves an area under the curve value of 0.966 for overall cancer detection. Detection sensitivity for early-stage patients achieves 73% at 99% specificity. Finally, we demonstrate the feasibility to accurately localize the origin of cancer signals with combined methylation and fragmentation profiling of tissue-specific accessible chromatin regions. Overall, this proof-of-concept study provides a technical platform to utilize multimodal cfDNA features for improved cancer detection.
@article{Bie2023THEMIS,title={Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization},author={Bie, F and Wang, Z and Y., Li and Guo, W. and Hong, Y. and Han, T. and Lv, F. and Yang, S. and Li, S. and Li, X. and Nie, P. and Xu, S. and Zang, R. and Zhang, M. and Song, P. and Feng, F. and Duan, J. and Bai, G. and Li, Y. and Huai, Q. and Zhou, B. and Huang, YS and Chen, W. and Tan, F. and Gao, S.},journal={Nature Communications},year={2023},doi={10.1038/s41467-023-41774-w},url={https://doi.org/10.1038/s41467-023-41774-w},dimensions={true},}
eGADA: enhanced Genomic Alteration Detection Algorithm, a fast Sparse-Bayesian-Learning based genomic segmentation algorithm
eGADA is an enhanced version of GADA, which is a fast segmentation algorithm utilizing the Sparse Bayesian Learning (or Relevance Vector Machine) technique from Tipping 2001. It can be applied to array intensity data, NGS sequencing coverage data, or any sequential data that displays characteristics of stepwise functions. Improvements by eGADA over GADA include: a) a customized Red-Black tree to significantly expedite the final backward elimination step of GADA; b) code in C++, which is safer and better structured than C; c) use Boost libraries extensively to provide user-friendly help and commandline argument processing; d) user-friendly input and output formats; e) export a dynamic library eGADA.so (packaged via Boost.Python) that offers API to Python; f) some bug fixes/optimization. The code is published at https://github.com/polyactis/eGADA.
@article{Huang2023eGADA,title={eGADA: enhanced Genomic Alteration Detection Algorithm, a fast Sparse-Bayesian-Learning based genomic segmentation algorithm},author={Huang, YS},journal={bioRxiv},year={2023},doi={10.1101/2023.08.20.553622},url={https://doi.org/10.1101/2023.08.20.553622},dimensions={true},}
Performance comparison of Accucopy, Sequenza, and ControlFreeC
Copy number alterations (CNAs) are an important type of genomic aberrations. It plays an important role in tumor pathogenesis and progression of cancer. It is important to detect regions of the cancer genome where copy number changes occur, which may provide clues that drive cancer progression. Deep sequencing technology provides genomic data at single-nucleotide resolution and is considered a better technique for detecting CNAs. There are currently many CNA-detection algorithms developed for whole genome sequencing (WGS) data. However, their detection capabilities have not been systematically investigated. Therefore, we selected three algorithms: Accucopy, Sequenza, and ControlFreeC, and applied them to data simulated under different settings. The results indicate that: 1) the correct inference of tumor sample purity is crucial to the inference of CNAs. If the tumor purity is wrongly inferred, the CNA detection will fail. 2) Higher sequencing depth and abundance of CNAs can improve performance. 3) Under the settings tested (sequencing depth at 5X or 30X, purity from 0.1 to 0.9, existence of subclones or not), Accucopy is the best-performing algorithm overall. For coverage=5X samples, ControlFreeC requires tumor purity to be above 50% to perform well. Sequenza can only perform well in high-coverage and more-CNA samples.
@article{Fan2023Accucopy_vs_others,title={Performance comparison of Accucopy, Sequenza, and ControlFreeC},author={Fan, X and Huang, YS},journal={bioRxiv},doi={10.1101/2023.09.03.556123},url={https://doi.org/10.1101/2023.09.03.556123},year={2023},dimensions={true},}
2022
Deffini
Deffini: A family-specific deep neural network model for structure-based virtual screening
Deep learning-based virtual screening methods have been shown to significantly improve the accuracy of traditional docking-based virtual screening methods. In this paper, we developed Deffini, a structure-based virtual screening neural network model. During training, Deffini learns protein-ligand docking poses to distinguish actives and decoys and then to predict whether a new ligand will bind to the protein target. Deffini outperformed Smina with an average AUC ROC of 0.92 and AUC PRC of 0.44 in 3-fold cross-validation on the benchmark dataset DUD-E. However, when tested on the maximum unbiased validation (MUV) dataset, Deffini achieved poor results with an average AUC ROC of 0.517. We used the family-specific training approach to train the model to improve the model performance and concluded that family-specific models performed better than the pan-family models. To explore the limits of the predictive power of the family-specific models, we constructed Kernie, a new protein kinase dataset consisting of 358 kinases. Deffini trained with the Kernie dataset outperformed all recent benchmarks on the MUV kinases, with an average AUC ROC of 0.745, which highlights the importance of quality datasets in improving the performance of deep neural network models and the importance of using family-specific models.
@article{Zhou2022Deffini,title={Deffini: A family-specific deep neural network model for structure-based virtual screening},author={Zhou, D and Liu, F and Zheng, Y and Hu, L and Huang, T and Huang, YS},journal={Computers in Biology and Medicine},year={2022},doi={10.1016/j.compbiomed.2022.106323},url={https://doi.org/10.1016/j.compbiomed.2022.106323},dimensions={true},}
UMI_ctDNA
Processing UMI Datasets at High Accuracy and Efficiency with the Sentieon ctDNA Analysis Pipeline
Liquid biopsy enables identification of low allele frequency (AF) tumor variants and novel clinical applications such as minimum residual disease (MRD) monitoring. However, challenges remain, primarily due to limited sample volume and low read count of low-AF variants. Because of the low AFs, some clinically significant variants are difficult to distinguish from errors introduced by PCR amplification and sequencing. Unique Molecular Identifiers (UMIs) have been developed to further reduce base error rates and improve the variant calling accuracy, which enables better discrimination between background errors and real somatic variants. While multiple UMI-aware ctDNA analysis pipelines have been published and adopted, their accuracy and runtime efficiency could be improved.
In this study, we present the Sentieon ctDNA pipeline, a fast and accurate solution for small somatic variant calling from ctDNA sequencing data. The pipeline consists of four core modules: alignment, consensus generation, variant calling, and variant filtering. We benchmarked the ctDNA pipeline using both simulated and real datasets, and found that the Sentieon ctDNA pipeline is more accurate than alternatives.
@article{Hu_2022_UMI_ctDNA,title={Processing UMI Datasets at High Accuracy and Efficiency with the Sentieon ctDNA Analysis Pipeline},author={Hu, J and Jiang, C and Huang, YS and Chen, HD and Feng, H and Freedman, D and Qu, Y and Fan, R and Su, Z and Chen, W},journal={bioRxiv},year={2022},doi={10.1101/2022.06.03.494742},url={https://doi.org/10.1101/2022.06.03.494742},dimensions={true},}
2021
Accucopy
Accucopy: Accurate and Fast Inference of Allele-specific Copy Number Alterations from Low-coverage Low-purity Tumor Sequencing Data
BACKGROUND:
Copy number alterations (CNAs), due to their large impact on the genome, have been an important contributing factor to oncogenesis and metastasis. Detecting genomic alterations from the shallow-sequencing data of a low-purity tumor sample remains a challenging task.
RESULTS:
We introduce Accucopy, a method to infer total copy numbers (TCNs) and allele-specific copy numbers (ASCNs) from challenging low-purity and low-coverage tumor samples. Accucopy adopts many robust statistical techniques such as kernel smoothing of coverage differentiation information to discern signals from noise and combines ideas from time-series analysis and the signal-processing field to derive a range of estimates for the period in a histogram of coverage differentiation information. Statistical learning models such as the tiered Gaussian mixture model, the expectation–maximization algorithm, and sparse Bayesian learning were customized and built into the model. Accucopy is implemented in C++ /Rust, packaged in a docker image, and supports non-human samples, more at http://www.yfish.org/software/.
CONCLUSIONS:
We describe Accucopy, a method that can predict both TCNs and ASCNs from low-coverage low-purity tumor sequencing data. Through comparative analyses in both simulated and real-sequencing samples, we demonstrate that Accucopy is more accurate than Sclust, ABSOLUTE, and Sequenza.
@article{Fan2021Accucopy,title={Accucopy: Accurate and Fast Inference of Allele-specific Copy Number Alterations from Low-coverage Low-purity Tumor Sequencing Data},author={Fan, X and Luo, G and Huang, YS},journal={BMC Bioinformatics},doi={10.1186/s12859-020-03924-5},url={https://doi.org/10.1186/s12859-020-03924-5},year={2021},publisher={BMC},dimensions={true},}
2018
Accurity
Accurity: accurate tumor purity and ploidy inference from tumor-normal WGS data by jointly modelling somatic copy number alterations and heterozygous germline single-nucleotide-variants
MOTIVATION:
Tumor purity and ploidy have a substantial impact on next-gen sequence analyses of tumor samples and may alter the biological and clinical interpretation of results. Despite the existence of several computational methods that are dedicated to estimate tumor purity and/or ploidy from The Cancer Genome Atlas (TCGA) tumor-normal whole-genome-sequencing (WGS) data, an accurate, fast and fully-automated method that works in a wide range of sequencing coverage, level of tumor purity and level of intra-tumor heterogeneity, is still missing.
RESULTS:
We describe a computational method called Accurity that infers tumor purity, tumor cell ploidy and absolute allelic copy numbers for somatic copy number alterations (SCNAs) from tumor-normal WGS data by jointly modelling SCNAs and heterozygous germline single-nucleotide-variants (HGSNVs). Results from both in silico and real sequencing data demonstrated that Accurity is highly accurate and robust, even in low-purity, high-ploidy and low-coverage settings in which several existing methods perform poorly. Accounting for tumor purity and ploidy, Accurity significantly increased signal/noise gaps between different copy numbers. We are hopeful that Accurity is of clinical use for identifying cancer diagnostic biomarkers.
AVAILABILITY:
Accurity is implemented in C++/Rust, https://github.com/polyactis/Accurity.
@article{Luo2018Accurity,title={Accurity: accurate tumor purity and ploidy inference from tumor-normal WGS data by jointly modelling somatic copy number alterations and heterozygous germline single-nucleotide-variants},author={Luo, Z and Fan, X and Huang, YS},journal={Bioinformatics},year={2018},doi={10.1093/bioinformatics/bty043},url={https://doi.org/10.1093/bioinformatics/bty043},dimensions={true},}
2015
VervetMonkeys
Sequencing strategies and characterization of 721 vervet monkey genomes for future genetic analyses of medically relevant traits.
YS
Huang, V
Ramensky
, SK
Service
, and
15 more authors
BACKGROUND:
We report here the first genome-wide high-resolution polymorphism resource for non-human primate (NHP) association and linkage studies, constructed for the Caribbean-origin vervet monkey, or African green monkey (Chlorocebus aethiops sabaeus), one of the most widely used NHPs in biomedical research. We generated this resource by whole genome sequencing (WGS) of monkeys from the Vervet Research Colony (VRC), an NIH-supported research resource for which extensive phenotypic data are available.
RESULTS:
We identified genome-wide single nucleotide polymorphisms (SNPs) by WGS of 721 members of an extended pedigree from the VRC. From high-depth WGS data we identified more than 4 million polymorphic unequivocal segregating sites; by pruning these SNPs based on heterozygosity, quality control filters, and the degree of linkage disequilibrium (LD) between SNPs, we constructed genome-wide panels suitable for genetic association (about 500,000 SNPs) and linkage analysis (about 150,000 SNPs). To further enhance the utility of these resources for linkage analysis, we used a further pruned subset of the linkage panel to generate multipoint identity by descent matrices.
CONCLUSIONS:
The genetic and phenotypic resources now available for the VRC and other Caribbean-origin vervets enable their use for genetic investigation of traits relevant to human diseases.
@article{Huang2015Vervet,title={Sequencing strategies and characterization of 721 vervet monkey genomes for future genetic analyses of medically relevant traits.},author={Huang, YS and Ramensky, V and Service, SK and Jasinska, AJ and Jung, Y and Choi, OW and Cantor, RM and Juretic, N and Wasserscheid, J and Kaplan, JR and Jorgensen, MJ and Dyer, TD and Dewar, K and Blangero, J and Wilson, RK and Warren, W and Weinstock, GM and Freimer, NB},journal={BMC Biology},year={2015},doi={10.1186/s12915-015-0152-2},url={https://doi.org/10.1186/s12915-015-0152-2},dimensions={true},}
2011
GWASDB
Analysis and visualization of Arabidopsis thaliana GWAS using web 2.0 technologies
YS
Huang, M
Horton
, BJ
Vilhjálmsson
, and
7 more authors
With large-scale genomic data becoming the norm in biological studies, the storing, integrating, viewing and searching of such data have become a major challenge. In this article, we describe the development of an Arabidopsis thaliana database that hosts the geographic information and genetic polymorphism data for over 6000 accessions and genome-wide association study (GWAS) results for 107 phenotypes representing the largest collection of Arabidopsis polymorphism data and GWAS results to date. Taking advantage of a series of the latest web 2.0 technologies, such as Ajax (Asynchronous JavaScript and XML), GWT (Google-Web-Toolkit), MVC (Model-View-Controller) web framework and Object Relationship Mapper, we have created a web-based application (web app) for the database, that offers an integrated and dynamic view of geographic information, genetic polymorphism and GWAS results. Essential search functionalities are incorporated into the web app to aid reverse genetics research. The database and its web app have proven to be a valuable resource to the Arabidopsis community. The whole framework serves as an example of how biological data, especially GWAS, can be presented and accessed through the web. In the end, we illustrate the potential to gain new insights through the web app by two examples, showcasing how it can be used to facilitate forward and reverse genetics research. Database: https://aragwas.1001genomes.org/
@article{Huang2011GWASDB,title={Analysis and visualization of Arabidopsis thaliana GWAS using web 2.0 technologies},author={Huang, YS and Horton, M and Vilhjálmsson, BJ and Seren, Ü and Meng, D and Meyer, C and Amer, MA and Borevitz, JO and Bergelson, J and Nordborg, M},journal={Database},year={2011},doi={10.1093/database/bar014},url={https://doi.org/10.1093/database/bar014},dimensions={true},}
2010
Thaliana_GWAS
Genome-wide association study of 107 phenotypes in a common set of Arabidopsis thaliana inbred lines
S
Atwell
, YS
Huang, BJ
Vilhjálmsson
, and
33 more authors
Although pioneered by human geneticists as a potential solution to the challenging problem of finding the genetic basis of common human diseases1,2, genome-wide association (GWA) studies have, owing to advances in genotyping and sequencing technology, become an obvious general approach for studying the genetics of natural variation and traits of agricultural importance. They are particularly useful when inbred lines are available, because once these lines have been genotyped they can be phenotyped multiple times, making it possible (as well as extremely cost effective) to study many different traits in many different environments, while replicating the phenotypic measurements to reduce environmental noise. Here we demonstrate the power of this approach by carrying out a GWA study of 107 phenotypes in Arabidopsis thaliana, a widely distributed, predominantly self-fertilizing model plant known to harbour considerable genetic variation for many adaptively important traits3. Our results are dramatically different from those of human GWA studies, in that we identify many common alleles of major effect, but they are also, in many cases, harder to interpret because confounding by complex genetics and population structure make it difficult to distinguish true associations from false. However, a-priori candidates are significantly over-represented among these associations as well, making many of them excellent candidates for follow-up experiments. Our study demonstrates the feasibility of GWA studies in A. thaliana and suggests that the approach will be appropriate for many other organisms.
@article{Atwell_2010_GWAS,title={Genome-wide association study of 107 phenotypes in a common set of Arabidopsis thaliana inbred lines},author={Atwell, S and Huang, YS and Vilhjálmsson, BJ and Willems, G and Horton, M and Li, Y and Meng, D and Platt, A and Tarone, A and Hu, TT and Jiang, R and Muliyati, NW and Zhang, X and Amer, MA and Baxter, I and Brachi, B and Chory, J and Dean, C and Debieu, M and de Meaux, J and Ecker, JR and Faure, N and Kniskern, JM and Jones, JD and Michael, T and Nemri, A and Roux, F and Salt, DE and Tang, C and Todesco, M and Traw, MB and Weigel, D and Marjoram, P and Borevitz, JO and Bergelson, J and Nordborg, M},journal={Nature},year={2010},doi={10.1038/nature08800},url={https://doi.org/10.1038/nature08800},dimensions={true},}
2007
NetworkAnnot
Systematic discovery of functional modules and context-specific functional annotation of human genome
MOTIVATION: The rapid accumulation of microarray datasets provides unique opportunities to perform systematic functional characterization of the human genome. We designed a graph-based approach to integrate cross-platform microarray data, and extract recurrent expression patterns. A series of microarray datasets can be modeled as a series of co-expression networks, in which we search for frequently occurring network patterns. The integrative approach provides three major advantages over the commonly used microarray analysis methods: (1) enhance signal to noise separation (2) identify functionally related genes without co-expression and (3) provide a way to predict gene functions in a context-specific way.
RESULTS: We integrate 65 human microarray datasets, comprising 1105 experiments and over 11 million expression measurements. We develop a data mining procedure based on frequent itemset mining and biclustering to systematically discover network patterns that recur in at least five datasets. This resulted in 143 401 potential functional modules. Subsequently, we design a network topology statistic based on graph random walk that effectively captures characteristics of a gene’s local functional environment. Function annotations based on this statistic are then subject to the assessment using the random forest method, combining six other attributes of the network modules. We assign 1126 functions to 895 genes, 779 known and 116 unknown, with a validation accuracy of 70%. Among our assignments, 20% genes are assigned with multiple functions based on different network environments.
@article{Huang2007NetworkAnnot,title={Systematic discovery of functional modules and context-specific functional annotation of human genome},author={Huang, YS and Li, H and Hu, H and Yan, X and Waterman, MS and Huang, H and Zhou, XJ},journal={Bioinformatics},year={2007},doi={10.1093/bioinformatics/btm222},url={https://doi.org/10.1093/bioinformatics/btm222},dimensions={true},}
